Results 251 to 260 of about 27,891 (280)
Some of the next articles are maybe not open access.
The national montelukast survey
Journal of Allergy and Clinical Immunology, 2005Randomized controlled trials have demonstrated the efficacy of montelukast for treating asthma; whether this can be extrapolated to clinical effectiveness in routine practice has yet to be established.To examine the use, effectiveness, and tolerability of montelukast in clinical practice for treating asthma and to explore prognostic factors that could ...
David Price +3 more
openaire +3 more sources
Montelukast Treatment of Urticaria
Annals of Pharmacotherapy, 2006Objective: To review clinical trial data to determine the benefits of using montelukast alone or as combination therapy in the treatment of urticaria. Data Sources: MEDLINE (1966–March 2006) and International Pharmaceutical Abstracts (1970–October 2005) were searched to find clinical trial publications that addressed the use of montelukast in urticaria.
Tyrone O McBayne, O'Rita M Siddall
openaire +3 more sources
Drugs, 2000
The tolerability of a medication, especially in children with asthma, is linked to a number of key factors. These include clinical effectiveness, adverse effects, frequency of drug regimen, ease and route of administration. and taste. Montelukast is unusual in that, in most countries, a licence for children aged > or =6 years was granted at the same ...
openaire +2 more sources
The tolerability of a medication, especially in children with asthma, is linked to a number of key factors. These include clinical effectiveness, adverse effects, frequency of drug regimen, ease and route of administration. and taste. Montelukast is unusual in that, in most countries, a licence for children aged > or =6 years was granted at the same ...
openaire +2 more sources
Montelukast in guidelines and beyond
Advances in Therapy, 2009In all asthma guidelines, preventive anti-inflammatory treatment is essential in all patients with persistent asthma. Inhaled corticosteroids are the mainstay of treatment in the control of asthma, but other treatments may be used as a monotherapy in patients with mild asthma or as an add-on treatment in those with moderate-to-severe asthma ...
Jean Bousquet +2 more
openaire +2 more sources
Montelukast for toddler asthma? A meta-analysis of montelukast in preschool wheeze
7.2 Paediatric Asthma and Allergy, 2016Background Wheeze in the preschool age has a high prevalence and healthcare burden. There is conflicting evidence of the effectiveness of montelukast, a leukotriene receptor antagonist, in preschool wheeze. Recent meta-analyses have focused on its use in viral induced or multiple-trigger wheeze, however such groups are unlikely to exist in real-life ...
Simon Broughton +9 more
openaire +2 more sources
Montelukast’s ability to fight COVID-19 infection
Journal of Asthma, 2020Montelukast can be effective in the treatment of SARS-CoV-2 infection.
A. Bozek, Janne Winterstein
semanticscholar +1 more source
Montelukast in the treatment of asthma and beyond
Expert Review of Clinical Immunology, 2009Asthma is a chronic inflammatory disease affecting over 300 million people worldwide. The common association with allergic rhinitis and the presence of proinflammatory cells and mediators in the circulation of patients qualify asthma as a systemic disease.
Leif Bjermer +2 more
openaire +3 more sources
Montelukast-Induced Generalized Urticaria
Annals of Pharmacotherapy, 2004OBJECTIVE: To report a case of generalized urticaria induced by montelukast treatment. CASE SUMMARY: A 28-year-old man with allergic rhinitis and moderate persistent asthma developed generalized urticaria 5 days after the initiation of montelukast and inhaled fluticasone. Symptoms disappeared within one day after suspension of both drugs.
MINCIULLO, PAOLA LUCIA +4 more
openaire +4 more sources
Montelukast pharmacokinetics in cystic fibrosis
The Journal of Pediatrics, 2003To determine if patients with cystic fibrosis (CF) have an altered pharmacokinetic profile of montelukast, we studied the single-dose pharmacokinetics in 12 patients with CF and 12 age- and gender-matched controls after they received a 10-mg oral dose.Plasma samples were collected before dosing and at 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 10, 12, and ...
Deon Wessler-Starman +3 more
openaire +3 more sources
Montelukast in pediatric asthma management
The Indian Journal of Pediatrics, 2006Leukotriene modifiers (receptor antagonist and biosynthesis inhibitor) represent the first mediator specific therapeutic option for asthma. Montelukast, a leukotriene receptor antagonist is the only such agent approved for use in pediatric patients. Montelukast modifies action of leukotrienes, which are the most potent bronchoconstrictors, by blocking ...
S. K. Kabra, Rakesh Lodha, Mandeep Walia
openaire +3 more sources